Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Takahiro Haeno"'
Autor:
Takahiro Haeno, Shinya Rai, Yoshiaki Miyake, Maiko Inoue, Ko Fujimoto, Aki Fujii, Yoshio Iwata, Shuji Minamoto, Takahide Taniguchi, Hiroaki Kakutani, Hiroaki Inoue, Takahiro Kumode, Kentaro Serizawa, Yasuhiro Taniguchi, Chikara Hirase, Yasuyoshi Morita, Hirokazu Tanaka, Yoichi Tatsumi, Takashi Ashida, Itaru Matsumura
Publikováno v:
Journal of Clinical and Experimental Hematopathology.
Autor:
Hitoshi Hanamoto, Yosaku Watatani, Hiroaki Inoue, Yoichi Tatsumi, Takahiro Haeno, Hirokazu Tanaka, Kazuto Nishio, Kazuko Sakai, J. Luis Espinoza, Yasuhiro Maeda, Chikara Hirase, Itaru Matsumura, Shinya Rai, Takahiro Kumode, Yasuhiro Taniguchi, Mitsuhiro Matsuda, Kentaro Serizawa, Takashi Ashida, Yasuyoshi Morita
Publikováno v:
Cancer science. 113(2)
We previously examined the utility of rituximab-bendamustine (RB) in patients with follicular lymphoma (FL) exhibiting less than optimal responses to two-cycles of R-CHOP. The aim of this study was to identify molecular biomarkers that can predict pr
Autor:
Hirokazu Tanaka, Yoichi Tatsumi, Yasuhiro Taniguchi, Chikara Hirase, Yosaku Watatani, Kentarou Serizawa, Kazuko Sakai, J. Luis Espinoza, Yasuyoshi Morita, Shinya Rai, Kazuto Nishio, Takahiro Kumode, Yasuhiro Maeda, Hiroaki Inoue, Hitoshi Hanamoto, Itaru Matsumura, Mitsuhiro Matsuda, Takashi Ashida, Takahiro Haeno
Background: Several clinical risk stratification models have been proposed to predict the clinical outcomes of follicular lymphoma (FL) cases, however, few reports are available to predict prognosis of FL cases receiving bendamustine-based regimens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d405cac2662540625cd1ede0c8988a2
https://doi.org/10.21203/rs.3.rs-648976/v1
https://doi.org/10.21203/rs.3.rs-648976/v1